HOME >> MEDICINE >> NEWS
New therapeutic targets for neurodegenerative diseases

The focus of work in the Neurosciences Departments Neurobiology Laboratory at the University of the Basque Countrys Faculty of Medicine and Odontology is the investigation of the molecular and cellular bases of neurodegenerative illnesses those that affect the brain and the spinal cord. Some of these neurodegenerative illnesses are well known and affect a significant part of the population, such as Alzheimers disease and multiple sclerosis.

Researchers at the University of the Basque Country (UPV-EHU) are studying the signals in the central nervous system - the brain and the spinal cord - that do not function well, in particular, those signals that cause the death of nerve cells. There are basically two types of cells in the central nervous system: neurones and the glial cells. Both types are sensitive to these functioning errors and both can die. In the case of Alzheimers disease, it is the neurones, above all, that die. However, in the case of multiple sclerosis, it is a class of glial cells known as oligodendrocytes that perish.

From in vitro cells to biological samples of human origin

The researchers at the Neurobiology Laboratory are investigating cells in cultures - neurones, oligodendrocytes or other cells of the nervous system -, and are trying to reproduce in vitro circumstances that are thought to be relevant in these ailments. That is to say, they are creating the conditions that cause the death of these cells, in order to determine what molecules intervene in the process from the moment of the lethal signal to the point where the cells collapse. In this type of experimental work a series of molecules involved in the death process are identified, the aim being to come up with pharmaceutical medicines that will improve treatment.

Apart from working with in vitro cells, they are also experimenting with animals that reproduce some of the elements involved in neurodegenerative illnesses u
'"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
10-May-2007


Page: 1 2 3

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. OCT1 required for therapeutic effects of diabetes drug Metformin
3. NeuroRx changes name to Neurotherapeutics
4. Olive Leaf report documents promising therapeutic interventions for 9-11 workers
5. T cells activated to fight HIV basis for dendritic cell therapeutic vaccine
6. Cerebrospinal fluid used to deliver therapeutics for Lou Gehrigs disease to brain
7. University to develop new therapeutics for cancer
8. Exubera: So far no evidence available of an additional therapeutic benefit
9. Nano-particles effective in killing cancer with one-two punch of chemotherapeutics
10. Researchers identify target for therapeutic drugs to fight most common adult brain cancer
11. Cedars-Sinai researchers demonstrate a new way to switch therapeutic genes on and off

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New therapeutic targets for neurodegenerative diseases

(Date:7/28/2015)... ... July 28, 2015 , ... BMI of Texas, which specializes in a variety ... weight loss surgery procedure. Committed to helping patients achieve their weight loss goals ... Texas is one of the first practices in South Texas to offer the ...
(Date:7/28/2015)... Nashville, Tenn. (PRWEB) , ... July 28, 2015 ... ... has added the SmileCareClub Invisible Aligner System to its online product ... , By using a teledentistry model and cloud-based technology, SmileCareClub allows patients to ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Women fear developing ... reason is that cancer, heart attack, and stroke are treatable, but there is little ... can do is to take part in a clinical trial, reports the July 2015 ...
(Date:7/28/2015)... ... 28, 2015 , ... The PULs Cardiac Test™ identifies asymptomatic ... many of whom are missed by conventional evaluation , A currently unmet ... sub-clinical disease, who are at risk of experiencing a coronary event, and for ...
(Date:7/28/2015)... ... July 28, 2015 , ... For ... Top Doctors, has based its selection process on the foundation of peer nominations. ... medical specialties, in any area of medicine and in any part of the ...
Breaking Medicine News(10 mins):Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 2Health News:BMI of Texas Now Offering Duodenal Switch Surgery – Weight Loss Procedure Helps Obese Patients Lose Weight Quickly 3Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3
(Date:7/28/2015)... -- According to a new market research report ... (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), ... published by MarketsandMarkets, the European Injectable Drug Delivery Market is ... in 2015, growing at a CAGR of 12.6% from 2015 ... market data T ables and 43 ...
(Date:7/27/2015)... July 28, 2015 CTI BioPharma Corp. (NASDAQ ... report its second quarter 2015 financial results on Thursday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Thursday, ...
(Date:7/27/2015)... DUBLIN and WESTLAKE VILLAGE, Calif. ... (NYSE: AGN ) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: ... Trade Commission (FTC) has granted early termination of the ... 1976 (HSR Act) with respect to Allergan,s pending acquisition ... On July 6, 2015, each of ...
Breaking Medicine Technology:European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9
Cached News: